期刊论文详细信息
Frontiers in Pharmacology 卷:12
Nanomedicines and Nanosimilars—Why a Robust Centralised Regulatory Framework Is Essential to Enhance Patient Safety
关键词: advocacy program;    centralised regulatory procedure;    hybrid application;    nanomedicines;    nanosimilars;    follow-on products;   
DOI  :  10.3389/fphar.2021.787239
来源: DOAJ
【 摘 要 】

【 授权许可】

Unknown   

  文献评价指标  
  下载次数:0次 浏览次数:3次